Posts tagged “PRA International”
Heat Bio's deal; Aerie's glaucoma advance; PRA's first results; BioCryst losses grow; BlackShades owner guilty
In today's Bulldog wrapup on technology and life science news: Heat Bio strikes a partnership for cancer therapies; Aerie reports promising test results for its glaucoma treatment; PRA reports first financials after IPO; BioCryst losses grow but generates revenue from own drug; and the owner of the BlackShades malware pleads guilty.
PRA Health Sciences, which was taken private in a $1.3 billion deal a year ago, is proceeding with plans for a return to the public markets with an IPO that could be worth as $492 million for the company, investors and the firms handling the offering.
PRA Health Sciences, which was taken private in a $1.3 billion deal a year ago, is looking to return to the public markets through a $375 million IPO.
PRA International's private equity owner KKR reportedly needs $950 million to finance its CRO acquisitions. Read more about the proposed offering.
PRA International had been exploring a possible initial public stock offering. Instead, it is being sold to private equity firm KKR. For the moment, companies involved are being quiet about most details - including the acquisition price. But media reports had estimated a selling price of around $1.3 billion.
Even as PRA International explores a possible initial public stock offering, the clinical trials firm is also reportedly the target of private equity bidders who could buy the company for up to $1.3 billion.
Another life science services firm in the Triangle, PRA International, may follow in the footsteps of a bigger rival - Quintiles - by offering stock in order to raise capital. Just two years ago, PRA was at the center of takeover rumors in the range of $1 billion.
Quintiles is tops in a survey of pharmaceutical firms. However, the report also finds disastisfaction also finds that nearly half would prefer to pick trial doctors to run studies rather than clinical research organizations such as Quintiles.
PRA has entered into a strategic partnership with Amgen to do work on a series of phase 3 studies to develop biosimilar drugs. Biosimilars are follow-on biologic drugs that are cheaper than very expensive biologic drugs.
The Raleigh-based life science services firm is in the process of an "auction," according to The Wall Street Journal. If so, PRA would be the second regional contract research organization sold this fall. PPD is being sold for $3.9 billion.
- FCC delays vote on much-disputed rules on cable boxes
- Stocks skid as drugmakers fall, then bank woes deepen losses
- Novo Nordisk: Clayton expansion proceeds, no NC layoffs despite cost cuts
- House lawmakers heap blistering criticism on Wells Fargo CEO
- Hundreds of tech jobs available at upcoming job fair